Language: BG BG
← Back to results
Not yet recruiting Phase 2 NCT07525427

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Phase 2 – studying effectiveness and dosage
Conditions: Drug Susceptible Pulmonary Tuberculosis

Sponsor: Gates Medical Research Institute

trial.available_in: БГ
Overview
The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.
Who can participate
Inclusion Criteria: * Age 18-65 years at consent * Body weight 35-100 kg at screening * Written informed consent obtained * Newly diagnosed rifampicin-sensitive pulmonary TB * Molecular confirmation of M. tuberculosis on Xpert MTB/RIF Ultra * ≥1+ AFB smear or Xpert Ultra low, medium, or high semi-quantitative result * Rifampicin sensitivity on molecular test * Chest X-ray consistent with TB (Investigator assessment) * Able to spontaneously produce sputum * Reproductive requirements met * Women of childbearing potential: 2 approved contraceptive methods or abstinence * Males: contraception or abstinence through 90 days post-dose Exclusion Criteria: * Prior anti-TB treatment for the current TB episode within 60 days * Prior medication active against Mtb within 3 months * Evidence of extra-thoracic TB, per investigator judgement * Prior treatment completion for TB within 3 years * 2 or more prior episodes of TB * Clinically significant history of or current medical condition posing safety risk * If HIV positive: * Not on ARVs or taking ARVs for \<3 months prior to screening OR * CD4+ count \<200cells/uL at screening OR * HIV viral load \>200 copies /mL at screening OR * AIDS infection or malignancies * Meets any of the following laboratory values during screening: * AST, ALT, or ALP ≥2.5× ULN * Total bilirubin ≥1.2× ULN * eGFR \<60 mL/min/1.73 m² * Hemoglobin \<9.0 g/dL (male) or \<8.5 g/dL (female) * White blood cell count \<2,000/mm³ * Absolute neutrophil count \<800/mm³ * Platelet count ≤100,000/mm³ * Positive hepatitis B surface antigen * Positive hepatitis C antibody * HbA1c ≥8.0% * Current or recent systemic immunosuppressive therapy, including corticosteroids * Significant drug or alcohol abuse affecting compliance or safety * Pregnant or breastfeeding, positive pregnancy test, or planning pregnancy shortly after treatment
Interventions
Bedaquiline, pretomanid and TBD09
DRUG
Bedaquiline, pretomanid and TBD09
DRUG
Bedaquiline, pretomanid and TBD09
DRUG
Bedaquiline, pretomanid and TBD09
DRUG
Bedaquiline, pretomanid and linezolid
DRUG
Locations 13
South Africa (13)
CHRU @ Isango Lethemba
Bethelsdorp , Gqeberha
Madibeng Centre for Research
Brits , North West
ONE MRI
Cape Town , Western Cape
TASK Applied Science - Brookylyn Chest Hospital
Cape Town , Western Cape
BioMedical Research Institute - Stellenbosch University @ Tygerberg Hospital
Cape Town , Western Cape
UCT Lung Institute
Cape Town , Western Cape
Desmond Tutu Health Foundation
Cape Town , Western Cape
Enhancing Care Foundation at Wentworth Hospital
Durban , Bluff
Sundrapragasen (Sandy) Pillay, MD
Synergy Biomedical Research Institute (SBRI)
East London
TASK Applied Science - Eden
George , Central
Clinical Research and HIV Research Unit (CHRU) @ Helen Joseph Hospital
Johannesburg , Gauteng
Setshaba Research Center
Pretoria , Soshangue
The Aurum Institute Tembisa
Tembisa , Gauteng
Technical details
Status
Not yet recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
65 Years
Healthy volunteers
No
Start date
10.04.2026
Completion date
05.11.2026
Registry ID
NCT07525427
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.